Old API Wind-down Ltd - Ordinary Shares ARLZQ

ARLZ will be discounted to cash

[GoldenDilemma]

Short sellers deem Toprol XL, Zontivity and Yosprala as worthless. Cash is ~.98c/share. Give it some time. 

Shorts will be proven wrong if and when good quarters come out showing the aforementioned drugs turn profits which exceed liabilities.

[kuatolives]

Awful to wach. Absolutely awful. 

[kuatolives]

Goldman sold half his stake this morning. What a bozo. He's as bad a trader as he is a "Pharma exec" who, for some reason, thought it was a good idea to wipe out his shareholders by trading steady growth for a massive single bet - that didn't pan out. I wonder if he realizes how much damage he's done A) with his actions at Trbute, and B) selling this pig to investors with

[snootchybootchy]

I'm shocked to hear this.  Isn't he on the board?  If he sold, it means he doesn't see much hope for Yosprala.  Isn't it way too early to sound the death knell for a new drug?  It hasn't even been six months yet.  I've read about lots of drugs that slowly gains traction after a disappointing launch.  There are other drugs that have much

[kuatolives]

He's on the seeking alpha board. He also said he is going to talk to Adams tomorrow - and if the guy has a direct line to Adams and is still dumping his stock... .well.... be aware of it.  Here's more of his drivel regarding a question regarding whether Deerfield might pull the credit line: Steven Goldman,Contributor Comments (543) |+ Follow |Send Message

[kuatolives]

Harris is on the board, not Goldman. 

[kuatolives]

Which is another joke in itself considering he wiped out his shareholders despite rising revenues - yet his advice is somehow coveted? Would be funny if it wasn't so sad.

[snootchybootchy]

Yes, you're right.  I was mistaken.  Goldman was on Tribute's board.

[Floridas2000]

I try not to sell when everyone is selling or buy when everyone is buying.  When a market goes into a frenzy they always overdo it on the up (SJL) and downside (ARLZ).  Investors stayed invested in ARLZ because of the sales team and acceptance of the drug along with becoming profitable this year.  It won't happen this year.  They got punished.  But punishing it to cash

[kuatolives]

I hope it comes back for the sake of the other shareholders, but my confidence was just shattered. My instincts tell me to get out, so I'm going to listen. My big fear is that Yosprala won't get adopted beyond a first prescription tryout as the doctor's go "Hey, give this a try," and the patient does, but doesn't renew the script because renewing scripts is a big pain

[AbNormAl]

Just took my punch in the gut. Banked on Adams and Yosprala... oh well, as a friend of mine used to say, "... sometimes you eats the bear and sometimes the bear eats you."